American Association for Cancer Research
Browse
15357163mct150427-sup-150137_2_supp_3511708_c7qpp6.png (2.35 MB)

Supplementary figure S2 from Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models

Download (2.35 MB)
figure
posted on 2023-04-03, 14:46 authored by Soon Young Park, Yuji Piao, Kang Jin Jeong, Jianwen Dong, John F. de Groot

Treatment with bevacizumab increases the expression of TGF beta1 via POSTN in GSC11 tumors.

Funding

M.G.Williams Memorial Brain Tumor Research

NCI

History

ARTICLE ABSTRACT

Periostin (POSTN) interacts with multiple integrins to coordinate a variety of cellular processes, including epithelial-to-mesenchymal transition (EMT) and cell migration. In our previous study, anti-VEGF-A therapy was associated with resistance and EMT. This study sought to determine the role of POSTN in the resistance of glioma stem cells (GSC) to antiangiogenic therapy. In mouse xenograft models of human glioma, POSTN expression was associated with acquired resistance to anti-VEGF-A therapy and had a synergistic effect with bevacizumab in prolonging survival and decreasing tumor volume. Resistance to anti-VEGF-A therapy regulated by POSTN was associated with increased expression of TGFβ1 and hypoxia-inducible factor-1α (HIF1α) in GSCs. At the molecular level, POSTN regulated invasion and expression of EMT (caveolin-1) and angiogenesis-related genes (HIF1α and VEGF-A) through activation of STAT3. Moreover, recombinant POSTN increased GSC invasion. Collectively, our findings suggest that POSTN plays an important role in glioma invasion and resistance to antiangiogenic therapy. Mol Cancer Ther; 15(9); 2187–97. ©2016 AACR.

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC